Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.

Published in: International journal of rheumatic diseases (2020)

In patients with RA with an inadequate response to DMARDs, tofacitinib 10 mg+MTX and peficitinib 150 mg+MTX were the most efficacious interventions and were not associated with a significant risk of serious adverse events.

Keyphrases

rheumatoid arthritis
disease activity
rheumatoid arthritis patients
systematic review
interstitial lung disease
ankylosing spondylitis
physical activity
ulcerative colitis
systemic sclerosis